HRP920667B1 - Application of fultripine active substance for preventing muscle deformation - Google Patents

Application of fultripine active substance for preventing muscle deformation

Info

Publication number
HRP920667B1
HRP920667B1 HRP-1227/91A HRP920667A HRP920667B1 HR P920667 B1 HRP920667 B1 HR P920667B1 HR P920667 A HRP920667 A HR P920667A HR P920667 B1 HRP920667 B1 HR P920667B1
Authority
HR
Croatia
Prior art keywords
fultripine
application
active substance
preventing muscle
muscle deformation
Prior art date
Application number
HRP-1227/91A
Other languages
English (en)
Inventor
Peter Emig
Original Assignee
Peter Emig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from YU122791A external-priority patent/YU48054B/sh
Application filed by Peter Emig filed Critical Peter Emig
Publication of HRP920667A2 publication Critical patent/HRP920667A2/xx
Publication of HRP920667B1 publication Critical patent/HRP920667B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
HRP-1227/91A 1990-07-14 1992-09-30 Application of fultripine active substance for preventing muscle deformation HRP920667B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (enExample) 1990-07-14 1991-06-04
YU122791A YU48054B (sh) 1990-07-14 1991-07-12 Postupak za proizvodnju farmaceutskog preparata

Publications (2)

Publication Number Publication Date
HRP920667A2 HRP920667A2 (en) 1996-10-31
HRP920667B1 true HRP920667B1 (en) 1998-06-30

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP-1227/91A HRP920667B1 (en) 1990-07-14 1992-09-30 Application of fultripine active substance for preventing muscle deformation

Country Status (30)

Country Link
US (2) US5162346A (enExample)
EP (2) EP0467164B1 (enExample)
KR (1) KR0182811B1 (enExample)
CN (1) CN1070700C (enExample)
AT (2) ATE206919T1 (enExample)
AU (1) AU634073B2 (enExample)
CA (1) CA2046943C (enExample)
CZ (1) CZ280879B6 (enExample)
DE (3) DE59107331D1 (enExample)
DK (2) DK0467164T3 (enExample)
EG (1) EG19814A (enExample)
ES (2) ES2164111T3 (enExample)
GR (1) GR3019179T3 (enExample)
HR (1) HRP920667B1 (enExample)
HU (1) HU206973B (enExample)
IE (1) IE74688B1 (enExample)
IL (1) IL98810A (enExample)
IN (1) IN172468B (enExample)
LT (1) LT3593B (enExample)
LV (1) LV10048B (enExample)
MC (1) MC2272A1 (enExample)
MX (1) MX9100160A (enExample)
NO (1) NO912758L (enExample)
NZ (1) NZ238940A (enExample)
PT (1) PT98291B (enExample)
RO (1) RO108220B1 (enExample)
RU (1) RU2070408C1 (enExample)
SI (1) SI9111227B (enExample)
SK (1) SK279567B6 (enExample)
ZA (1) ZA915466B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
MXPA02000997A (es) * 1999-08-03 2003-10-14 Awd Pharma Gmbh & Co Kg Uso de flupirtina para aliviar el dolor ocasionado por enfermedades degenerativas de las articulaciones en perros y gatos.
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
CN101790374A (zh) * 2007-08-01 2010-07-28 H.隆德贝克有限公司 Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
EP0193056B1 (de) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Also Published As

Publication number Publication date
PT98291B (pt) 1999-01-29
CZ280879B6 (cs) 1996-04-17
AU634073B2 (en) 1993-02-11
HU912359D0 (en) 1991-12-30
LT3593B (en) 1995-12-27
EP0467164A3 (en) 1992-04-15
DE59109222D1 (de) 2001-11-22
DK0467164T3 (da) 1996-03-04
SK279567B6 (sk) 1999-01-11
HUT59313A (en) 1992-05-28
RU2070408C1 (ru) 1996-12-20
KR0182811B1 (ko) 1999-05-01
EP0659410A3 (de) 1995-10-25
NO912758L (no) 1992-01-15
HU206973B (en) 1993-03-01
IL98810A0 (en) 1992-07-15
SI9111227A (en) 1995-06-30
ES2164111T3 (es) 2002-02-16
IE74688B1 (en) 1997-07-30
NZ238940A (en) 1997-05-26
DE59107331D1 (de) 1996-03-14
RO108220B1 (ro) 1994-03-31
CS210191A3 (en) 1992-02-19
US5162346A (en) 1992-11-10
MC2272A1 (fr) 1993-06-23
NO912758D0 (no) 1991-07-12
EP0467164A2 (de) 1992-01-22
PT98291A (pt) 1992-05-29
KR920002147A (ko) 1992-02-28
AU8040391A (en) 1992-01-16
US5284861A (en) 1994-02-08
IE912451A1 (en) 1992-01-15
IN172468B (enExample) 1993-08-14
ES2082887T3 (es) 1996-04-01
SI9111227B (sl) 2000-12-31
MX9100160A (es) 1992-02-28
CA2046943C (en) 1996-03-12
EP0659410B1 (de) 2001-10-17
EP0467164B1 (de) 1996-01-31
IL98810A (en) 1996-01-19
GR3019179T3 (en) 1996-06-30
HRP920667A2 (en) 1996-10-31
DE4122166A1 (de) 1992-01-16
CN1058716A (zh) 1992-02-19
ATE133564T1 (de) 1996-02-15
CA2046943A1 (en) 1992-01-15
ZA915466B (en) 1992-04-29
EP0659410A2 (de) 1995-06-28
LV10048A (lv) 1994-05-10
EG19814A (en) 1996-02-29
DK0659410T3 (da) 2001-12-27
CN1070700C (zh) 2001-09-12
LTIP919A (en) 1995-03-27
LV10048B (en) 1995-06-20
ATE206919T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
HRP920667A2 (en) Application of fultripine active substance for preventing muscle deformation
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
TW218869B (enExample)
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
HU9502585D0 (en) Use of riluzole for treating aids-related neural disorders
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
AU8656491A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
ZA9010080B (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
GR3015462T3 (en) Dynamic redression splint for the therapy of the forefoot adduction.
NO881768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
SE8703308D0 (sv) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
AR245225A1 (es) Composiciones para el tratamiento de cuero.
NO950842L (no) Diarylpiperazinoacetamidforbindelser som antimuskariniske midler
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
AU4533693A (en) N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treatment of circulatory disorders
IL106917A0 (en) Compositions for the treatment of skin disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: AWD. PHARMA GMBH & CO. KG, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100702

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20110713